IL295050A - Estrogen receptor modulators - Google Patents

Estrogen receptor modulators

Info

Publication number
IL295050A
IL295050A IL295050A IL29505022A IL295050A IL 295050 A IL295050 A IL 295050A IL 295050 A IL295050 A IL 295050A IL 29505022 A IL29505022 A IL 29505022A IL 295050 A IL295050 A IL 295050A
Authority
IL
Israel
Prior art keywords
optionally substituted
compound
mmol
alkyl
methyl
Prior art date
Application number
IL295050A
Other languages
English (en)
Hebrew (he)
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of IL295050A publication Critical patent/IL295050A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/38—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing five carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/60—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members
    • C07C2603/62—Ring systems containing bridged rings containing three rings containing at least one ring with less than six members containing three- or four-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL295050A 2016-04-01 2017-03-29 Estrogen receptor modulators IL295050A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662317254P 2016-04-01 2016-04-01
PCT/US2017/024809 WO2017172957A1 (en) 2016-04-01 2017-03-29 Estrogen receptor modulators

Publications (1)

Publication Number Publication Date
IL295050A true IL295050A (en) 2022-09-01

Family

ID=59966438

Family Applications (3)

Application Number Title Priority Date Filing Date
IL295050A IL295050A (en) 2016-04-01 2017-03-29 Estrogen receptor modulators
IL285318A IL285318B (en) 2016-04-01 2017-03-29 Estrogen receptor modulators
IL261654A IL261654B (en) 2016-04-01 2018-09-06 Estrogen receptor modulators

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL285318A IL285318B (en) 2016-04-01 2017-03-29 Estrogen receptor modulators
IL261654A IL261654B (en) 2016-04-01 2018-09-06 Estrogen receptor modulators

Country Status (15)

Country Link
US (5) US20190142811A1 (enExample)
EP (1) EP3442971B1 (enExample)
JP (2) JP6926189B2 (enExample)
KR (2) KR20220071293A (enExample)
CN (4) CN112679495B (enExample)
AR (1) AR108011A1 (enExample)
AU (3) AU2017242027B2 (enExample)
CA (1) CA3017388C (enExample)
ES (1) ES2991862T3 (enExample)
IL (3) IL295050A (enExample)
MX (2) MX392461B (enExample)
RU (1) RU2738646C2 (enExample)
SG (1) SG11201807708SA (enExample)
TW (2) TW202235418A (enExample)
WO (1) WO2017172957A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6905539B2 (ja) 2016-02-05 2021-07-21 インベンティスバイオ リミテッド ライアビリティ カンパニー 選択的エストロゲン受容体分解剤およびその使用
CN112679495B (zh) 2016-04-01 2023-03-28 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
CN107814798B (zh) * 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
WO2018130124A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用
EP3665142A4 (en) 2017-09-11 2021-04-28 Recurium IP Holdings, LLC CONTINUOUS CURRENT PROCESS FOR THE PRODUCTION OF BICYCLIC CONNECTIONS
JP2021503448A (ja) * 2017-11-16 2021-02-12 ノバルティス アーゲー Ｌｓｚ１０２及びリボシクリブを含む医薬組合せ
WO2020238733A1 (zh) * 2019-05-24 2020-12-03 浙江海正药业股份有限公司 丙烯酸类衍生物的晶型及其制备方法和用途
MX2022001149A (es) * 2019-08-06 2022-04-06 Recurium Ip Holdings Llc Moduladores del receptor de estrógeno para el tratamiento de mutantes.
MX2022005139A (es) * 2019-11-04 2022-06-24 Recurium Ip Holdings Llc Sales y formas de un modulador de receptores estrogénicos.
WO2021127042A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
AU2020407573A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
MX2022007627A (es) 2019-12-20 2022-08-16 Recurium Ip Holdings Llc Combinaciones.
KR20220119418A (ko) * 2019-12-20 2022-08-29 리커리엄 아이피 홀딩스, 엘엘씨 조합물
WO2021127046A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
IL297448A (en) * 2020-04-22 2022-12-01 Recurium Ip Holdings Llc Preparation of an selective estrogen receptor degrader
WO2021253380A1 (en) * 2020-06-19 2021-12-23 InventisBio Co., Ltd. Oral formulations and uses thereof
AU2021343525A1 (en) * 2020-09-20 2023-05-18 Tactogen Inc Advantageous tryptamine compositions for mental disorders or enhancement
WO2022133446A1 (en) * 2020-12-16 2022-06-23 Recurium Ip Holdings, Llc Combinations
EP4267578A4 (en) * 2020-12-23 2024-11-20 Recurium IP Holdings, LLC ESTROGEN RECEPTOR MODULATORS
WO2022153268A1 (en) 2021-01-15 2022-07-21 Beckley Psytech Limited Tryptamine analogues
EP4366734A4 (en) * 2021-07-08 2025-05-21 Olema Pharmaceuticals, Inc. METHODS OF TREATING DISEASES ASSOCIATED WITH ESTROGEN RECEPTOR

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09510216A (ja) 1994-03-11 1997-10-14 イーライ・リリー・アンド・カンパニー ５−ｈｔ▲下２ｂ▼受容体に関連する病態を治療するための方法
GB9604996D0 (en) 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
EP1438310B1 (en) 2001-10-19 2006-12-20 TransTech Pharma Inc. Beta-carbolin derivatives as ptp-inhibitors
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
JP2008508356A (ja) 2004-08-02 2008-03-21 スミスクライン ビーチャム コーポレーション Ｈｐｖ感染に有用な化合物
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
WO2008002490A2 (en) 2006-06-23 2008-01-03 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
CA2683444A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
TW201028414A (en) * 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
CN106167488A (zh) * 2009-05-27 2016-11-30 Ptc医疗公司 治疗癌症及非肿瘤病症的方法
ES2567328T3 (es) * 2009-07-28 2016-04-21 Ono Pharmaceutical Co., Ltd. Compuesto bicíclico y uso del mismo para fines médicos
KR20120125468A (ko) 2010-01-15 2012-11-15 머크 샤프 앤드 돔 코포레이션 항당뇨 화합물로서 옥사디아졸 베타 카르볼린 유도체
ES2822130T3 (es) * 2010-02-11 2021-04-29 Bristol Myers Squibb Co Macrociclos como inhibidores del factor XIa
WO2011103487A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
PL2580210T3 (pl) 2010-06-10 2017-09-29 Seragon Pharmaceuticals, Inc. Modulatory receptora estrogenowego i ich zastosowania
US9029574B2 (en) * 2011-01-27 2015-05-12 Ono Pharmaceutical Co., Ltd. Bicyclic compound and use thereof for medical purposes
CN102432608B (zh) 2011-11-01 2013-04-17 浙江大学 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法
WO2013090829A1 (en) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
PT2797921T (pt) * 2011-12-31 2017-11-14 Beigene Ltd Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp
CN104220065A (zh) * 2012-02-07 2014-12-17 Eolas治疗公司 取代的脯氨酸/哌啶用作食欲素受体拮抗剂
AU2013235499A1 (en) 2012-03-20 2014-09-25 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
PT2872482T (pt) 2012-07-13 2020-09-22 Oncternal Therapeutics Inc Método de tratamento de cancro de mama com modulador seletivo do recetor de andrógeno (sarm)
JP6364028B2 (ja) 2013-02-19 2018-07-25 ノバルティス アーゲー 選択的エストロゲン受容体ディグレーダーとしてのベンゾチオフェン誘導体およびその組成物
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
CA2911859A1 (en) * 2013-05-28 2014-12-04 Astrazeneca Ab Chemical compounds
AU2014358850A1 (en) 2013-12-06 2016-06-16 F. Hoffmann-La Roche Ag Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
CN104693211A (zh) 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
WO2015123355A1 (en) * 2014-02-12 2015-08-20 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US9695166B2 (en) * 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
WO2015173329A1 (en) 2014-05-16 2015-11-19 Actelion Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
KR102505901B1 (ko) 2014-06-27 2023-03-08 노그라 파마 리미티드 아릴 수용체 조정제, 및 그의 제조 및 사용 방법
KR101997592B1 (ko) 2014-10-09 2019-07-08 광동 쫑성 파마세티컬 컴패니, 리미티드 히드록시퓨린계 화합물 및 이의 응용
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
JP6786520B2 (ja) 2015-04-21 2020-11-18 ジーティーエックス・インコーポレイテッド 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンド及びその使用方法
CA2988620A1 (en) * 2015-06-16 2016-12-22 Jiangsu Hengrui Medicine Co., Ltd. Piperidine derivative and preparation method and pharmaceutical use thereof
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
JP6905539B2 (ja) * 2016-02-05 2021-07-21 インベンティスバイオ リミテッド ライアビリティ カンパニー 選択的エストロゲン受容体分解剤およびその使用
CN112679495B (zh) 2016-04-01 2023-03-28 里科瑞尔姆Ip控股有限责任公司 雌激素受体调节剂
JP6956747B2 (ja) 2016-06-10 2021-11-02 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンドおよびその使用方法
CN109415361B (zh) * 2016-06-29 2022-03-08 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
CN110139674B (zh) * 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用

Also Published As

Publication number Publication date
TWI746535B (zh) 2021-11-21
BR112018070161A2 (pt) 2019-02-12
RU2018132037A (ru) 2020-05-12
CN112745316A (zh) 2021-05-04
EP3442971A1 (en) 2019-02-20
TW202235418A (zh) 2022-09-16
US20200261428A1 (en) 2020-08-20
US20200261429A1 (en) 2020-08-20
CN112679495B (zh) 2023-03-28
EP3442971C0 (en) 2024-09-25
MX392461B (es) 2025-03-11
AU2020294196B2 (en) 2022-06-16
US11065233B2 (en) 2021-07-20
JP2019515026A (ja) 2019-06-06
CN109311870B (zh) 2021-09-21
RU2738646C2 (ru) 2020-12-15
MX2022005780A (es) 2022-06-09
JP2021176911A (ja) 2021-11-11
MX2018011419A (es) 2019-06-06
IL285318A (en) 2021-09-30
IL285318B (en) 2022-09-01
CN113717170A (zh) 2021-11-30
IL261654A (en) 2018-10-31
US11065234B2 (en) 2021-07-20
US20200261430A1 (en) 2020-08-20
ES2991862T3 (es) 2024-12-05
AR108011A1 (es) 2018-07-04
KR20190002478A (ko) 2019-01-08
EP3442971B1 (en) 2024-09-25
KR102401841B1 (ko) 2022-05-25
CN112679495A (zh) 2021-04-20
IL261654B (en) 2021-08-31
SG11201807708SA (en) 2018-10-30
JP6926189B2 (ja) 2021-08-25
US20210330651A1 (en) 2021-10-28
CN109311870A (zh) 2019-02-05
WO2017172957A1 (en) 2017-10-05
AU2017242027A1 (en) 2018-10-11
AU2022204025A1 (en) 2022-06-30
AU2017242027B2 (en) 2020-10-08
CA3017388C (en) 2024-03-12
US10959989B2 (en) 2021-03-30
US20190142811A1 (en) 2019-05-16
CA3017388A1 (en) 2017-10-05
KR20220071293A (ko) 2022-05-31
RU2018132037A3 (enExample) 2020-05-15
TW201736334A (zh) 2017-10-16
EP3442971A4 (en) 2020-01-01
AU2020294196A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
IL295050A (en) Estrogen receptor modulators
CN115038450A (zh) 组合
JP7794448B2 (ja) 組み合わせ
BR112021005260A2 (pt) antagonista de dp
HK40064960A (en) Estrogen receptor modulators
HK40052769A (en) Estrogen receptor modulators
RU2845443C1 (ru) Комбинации
BR112018070161B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso dos mesmos e método para inibir o crescimento de célula
HK40004087A (en) Estrogen receptor modulators
HK40004087B (en) Estrogen receptor modulators
CN115023228A (zh) 组合
CN115103673A (zh) 组合